Wednesday, July 18, 2018
 
 
Company News: Page (1) of 1 - 07/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
AGC to Expand GMP-Compliant Synthetic Pharmaceutical Intermediate and Active Ingredient Production Capacity Tenfold
- Broadened CDMO Business Will Cover Commercial New Drugs As Well As in Development Stage of Ones -
(July 12, 2018)

TOKYO, July 12, 2018 /PRNewswire/ -- AGC Inc., a world-leading manufacturer of glass, chemicals and high-tech materials, announced on July 12 a major expansion of facilities at its Chiba Plant that will result in an approximately tenfold increase in the company's GMP(*1)-compliant synthetic pharmaceutical intermediate and active ingredient (*2) production capacity. The new capacity is set to come online in October 2019.

AGC began developing and manufacturing pharmaceutical and agrochemical intermediates and active ingredients on a contract basis in the 1980s. Leveraging its edge in fluorine technologies and extensive experience in in-house drug discovery and other fields, AGC now offers a range of CDMO (*3) services tailored to customer needs.

While AGC has to date mainly provided CDMO services for in the development stage of new drugs, this expansion will give AGC the end-to-end capability to produce commercial drugs too, allowing it to deliver more advanced one-stop solutions. The new facilities will also be capable of producing hard-to-handle active ingredients, such as the highly potent active pharmaceutical ingredients typically used in cancer therapy. AGC will therefore be able to meet a wider
range of customer demand.



The AGC Group's "AGC plus" management policy identifies the life sciences as one of its strategic businesses. Moving forward, the group will continue to invest in the capacity needed to meet ongoing growth in demand for pharmaceutical intermediate and active ingredient CDMO services.

(*1) GMP: Good manufacturing practice (standards governing the production and quality control of pharmaceutical products and quasi-drugs).

(*2) Synthetic pharmaceutical intermediates and active ingredients: Intermediates and active ingredients for pharmaceutical products that are produced by chemical synthesis.

(*3) CDMO: Contract development and manufacturing organization (a company that develops production methods and manufactures products for another company on a contract basis).

For more information, please visit: https://kyodonewsprwire.jp/attach/201807095798-O1-vIa55jNK.pdf

About the AGC Group

AGC Inc. (Headquarters: Tokyo, President & CEO: Takuya Shimamura) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs some 50,000 people worldwide and generates annual sales of approximately 1.5 trillion Japanese yen through business in about 30 countries. For more information, please visit: http://www.agc.com/en/.

* The company changed its name from Asahi Glass Co., Ltd. to AGC Inc. on July 1, 2018.

Cision View original content:http://www.prnewswire.com/news-releases/agc-to-expand-gmp-compliant-synthetic-pharmaceutical-intermediate-and-active-ingredient-production-capacity-tenfold-300679858.html

SOURCE AGC Inc.

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords: Inc.,Science,Medical,Cancer,Business,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Robotics Prosthetics Market Exclusive Analysis by MRFR | Industry Growing with 9.5% CAGR up to 2027 | The Demand for Robotic Prosthetic is Found to be Increasing across the Globe
  • Implantable Medical Devices Market Predicted to be Worth US$ 49.8 Bn by 2024, Says TMR
  • Global Cosmetic Chemicals Industry
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally - QYResearch.com
  • Association of Community Cancer Centers and Advisory Board Launch 9th Annual Trends in Cancer Care Survey
  • Small Animal Imaging Market is Estimated to Grow at a Faster Pace With the Significant CAGR During the Forecast Period: Radiant Insights, Inc.
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines